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SUMMARY
Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease. CAV1 and CAV2 organize
membrane lipid rafts (MLRs) important for cell signaling and neuronal survival, and overexpression of
CAV1 ameliorates ALS phenotypes in vivo. Genome-wide association studies localize a large proportion of
ALS risk variants within the non-coding genome, but further characterization has been limited by lack
of appropriate tools. By designing and applying a pipeline to identify pathogenic genetic variation within
enhancer elements responsible for regulating gene expression, we identify disease-associated variation
within CAV1/CAV2 enhancers, which replicate in an independent cohort. Discovered enhancer mutations
reduce CAV1/CAV2 expression and disrupt MLRs in patient-derived cells, and CRISPR-Cas9 perturbation
proximate to a patient mutation is sufficient to reduce CAV1/CAV2 expression in neurons. Additional enrich-
ment of ALS-associated mutations within CAV1 exons positions CAV1 as an ALS risk gene. We propose
CAV1/CAV2 overexpression as a personalized medicine target for ALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a universally fatal and rela-
tively common neurodegenerative disease. Progress has been
made in identification of highly penetrant coding-sequence mu-
tations responsible for monogenic ALS, but the majority of spo-
radic ALS patients have no identified genetic risk factor despite
heritability estimates as high as 52% (Ryan et al., 2019; Trabjerg
et al., 2020). Importantly, discovery of genetic risk factors often
leads to therapeutic targets.
ALS is defined bymotor neuron death within the CNS; inmotor
neurons, caveolin 1 (CAV1) and caveolin 2 (CAV2) are expressed
together in a hetero-oligomeric complex (de Almeida, 2017)
within membrane lipid rafts (MLRs) on the cell surface and
have a key role in organization of intercellular signaling (Sawada
et al., 2019; Schmick and Bastiaens, 2014). CAV1 activity pro-
motes neurotrophic signaling, leading to enhanced neuronal sur-
vival (Head et al., 2011; Mandyam et al., 2017). In contrast, loss
of CAV1 accelerates neurodegeneration (Head et al., 2010,
2011). Abnormal neurotrophic signaling is well documented in
ALS (Mutoh et al., 2000; Turner et al., 2004), and in particular,
deficient neurotrophic signaling is associated with an increased
vulnerability to neuronal injury (Bemelmans et al., 2006; Ghavami
et al., 2014; Kowianski et al., 2018; Tooze and Schiavo, 2008).
There are ongoing efforts to rebalance neurotrophic signaling
in ALS patients (Berry et al., 2019); interestingly, neuronal over-
expression of CAV1 improves survival and reduces motor
neuron death in a mouse model of ALS (Sawada et al., 2019)
and is being developed as a therapy for ALS (US patent no.
8969077B2) (Head et al., 2012).
Genome-wide association studies suggest a significant pro-
portion of missing heritability for ALS is distributed throughout
non-coding chromosomal regions (van Rheenen et al., 2016).
Indeed, a large proportion of human DNA under evolutionary
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constraint (Ward and Kellis, 2012) is non-coding, and mutations
in non-coding DNA affect biological fitness (Graur, 2017), sug-
gesting an important role in all aspects of cellular function. To
date, genetic discoveries within the non-coding genome have
been limited by a shortage of appropriate methodology.
The non-coding genome contains regions that regulate
expression of coding genes; these regions include enhancers,
which are cis-acting DNA sequences that modulate expression
of target genes primarily through binding of transcription factors
(TFs) (Koch et al., 2011). Physical interaction between an
enhancer and the promoter of the target gene is mediated by
DNA looping (Pennacchio et al., 2013).We have designed a pipe-
line for identification of disease-associated genetic variation
within enhancers; variants are aggregated according to function,
filtered based on evolutionary conservation (Hujoel et al., 2019),
and collapsed into a single burden test (Cirulli and Goldstein,
2010).
We hypothesized that genetic variation within enhancers
linked to expression of CAV1 and CAV2 would be associated
with risk of ALS. Application of our pipeline confirmed our hy-
pothesis and places this pathway upstream in the development
of neurodegeneration.
RESULTS
Association of Regulatory Enhancer Elements with
Coding Genes
Aggregation of genetic material with a common biological func-
tion improves power to detect genetic association via burden
testing (Cirulli and Goldstein, 2010). We have aggregated sets
of enhancers that regulate a common coding gene. As previously
described (Fishilevich et al., 2017), we identified high-quality
manually curated links between enhancers and coding genes
based on agreement between correlated expression between
genes, enhancer-RNAs (eRNAs), and TFs; expression quantita-
tive trait loci (eQTL) within enhancers; capture Hi-C; and gene-
enhancer genomic distances. Gene-enhancer relationships
may be cell type specific (Heinz et al., 2015), whereas our
method is cell and tissue agnostic. The disadvantage of this is
that highly cell-specific relationships may be missed; however,
by including data from multiple cell types, our method benefits
from an increase in the quantity of high-quality training data.
Moreover, many previously identified ALS-associated mutations
are widely expressed (Cooper-Knock et al., 2013). Enhancers
linked to CAV1 and CAV2 are detailed in Table S1.
A Pipeline for Testing for Disease-Associated Genetic
Variation within Enhancers
Our pipeline for testing for disease-associated genetic variation
within enhancers is detailed in Figure 1A. Following the aggrega-
tion of enhancers linked to individual coding genes, we filtered
enhancer variants to remove those unlikely to be pathogenic
prior to association testing. Enhancer variants were included if
minor allele frequency (MAF) < 0.01 (Lek et al., 2016; van Rhee-
nen et al., 2016) and LINSIGHT (Huang et al., 2017) score >0.8.
LINSIGHT score >0.8 is consistent with strong evolutionary se-
lection (Huang et al., 2017). Following filtering, case and control
variant frequencies for each set of enhancers were collapsed
into a single SKAT burden test (STARMethods; Lee et al., 2012).
We tested our pipeline using whole-genome sequencing
(WGS) data from 4,495 ALS cases and 1,925 controls (Project
MinE; Data-Freeze-1). First, we hypothesized correctly that
aggregated enhancers linked to all genes within the ‘‘amyotro-
phic lateral sclerosis’’ KEGG pathway (Kanehisa et al., 2017)
would be enriched with ALS-associated genetic variation
(SKAT-O; p = 0.02; 377 variants). Second, we hypothesized
that pathogenic enhancer variants are likely to cause reduced
transcription of their target coding gene, which might be ex-
pected to mimic a haploinsufficiency mechanism. Therefore,
we examined variants within enhancers linked to expression of
TBK1, which is uniquely known to cause ALS via haploinsuffi-
ciency (Freischmidt et al., 2015). Consistent with our hypothesis,
genetic variation within TBK1 enhancers is significantly associ-
ated with ALS (p = 0.003; SKAT-O; 12 variants; Table S1). Finally,
expression of TBK1was reduced in patient-derived lymphoblas-
toid cells carrying an ALS-associated chr12:65059913G>A mu-
tation within a TBK1 enhancer compared to mean expression
in cells derived from neurologically normal controls, although
this difference was not statistically significant (24% reduction;
p = 0.27; Welch’s t test; Figure S2).
Genetic Variation within CAV1/CAV2 Enhancers Is
Linked to ALS
We applied our pipeline to test for genetic association within en-
hancers linked to CAV1 and CAV2 expression. We discovered
significant enrichment of ALS-associated genetic variation
within enhancers linked to CAV1 (p = 3.88 3 105; SKAT-O; 40
variants) and CAV2 (p = 1.52 3 105; 57 variants). In total, 56
(1.2%) sporadic ALS patients carry one or more ALS-associated
variants within CAV1/CAV2 enhancers compared to 2 (0.1%) of
controls (risk ratio = 12.0). There is significant overlap between
enhancers and ALS-associated variants linked to CAV1 and
CAV2 (Tables S1 and S3), which reflects shared function be-
tween the two proteins.
As a final test of our pipeline, we applied our analysis to
all well-annotated genes found within KEGG pathways
(n = 3,761). In this analysis, CAV1 and CAV2 enhancers carry
the most significant enrichment with ALS-associated mutations
compared to all other genes (Figure 1B). Importantly, there was
no inflation of p values to indicate false positives (lGC 1,000 =
1.07).
Genetic Variation within CAV1 CNS Enhancers Is
Associated with ALS
To test whether ALS-associated genetic variation within CAV1/
CAV2 enhancers is relevant within the CNS, we re-tested for ge-
netic association using CNS-specific enhancers. A recent study
released Hi-C data from CNS neurons (Rhie et al., 2018). We
used these data to recalculate enhancer-gene relationships for
CAV1 (Table S1); no data were available for CAV2. Despite a
significant change in the number and location of aggregated var-
iants (Figure 1C), genetic variation within CAV1 CNS enhancers
was still significantly associated with ALS (SKAT-O; p =
6.36E05; 128 variants; Table S3); 188 (4.1%) ALS patients




carried an ALS-associated CAV1 CNS enhancer risk variant
compared to 17 (0.9%) of controls (risk ratio = 4.6).
Replication of ALS-Associated Genetic Variation within
CAV1 and CAV2 Enhancers
To validate observed genetic association within CAV1/CAV2 en-
hancers, we obtained WGS data from an independent cohort of
1,685 ALS patients and 445 controls (Project MinE; Data-Freeze-
2). Derived tissue-agnostic CAV1/CAV2 enhancers were not
sufficiently variable in this smaller cohort (<10 variants), though
Hi-C-derived CNS enhancers contained more genetic material.
Re-applying our pipeline to CAV1 Hi-C-derived CNS enhancers
in the validation cohort revealed significant enrichment of ALS-
associated genetic variation (p = 0.03; SKAT-O; 51 variants; Ta-
ble S3); 60 (3.6%) ALS patients carried an ALS-associated CAV1
CNS enhancer risk variant compared to 3 (0.7%) of controls (risk
ratio = 5.1).
Figure 1. Significant Enrichment of ALS Ge-
netic Risk within Enhancers and Coding Re-
gions Linked to CAV1 and CAV2
(A) Pipeline for variant filtering and burden testing;
enhancers are first associatedwith genes based on
epigenetic and transcriptome data (Fishilevich
et al., 2017); enhancer variants are prioritized for
further analysis if they are rare (MAF < 0.01; Lek
et al., 2016) and evolutionary conserved (LINSIGHT
score > 0.8; Huang et al., 2017).
(B) Q-Q plot depicting on x axis the log 10 of
expected p value versus the actually measured p
value for 3,761 enhancer groups using whole-
genome sequencing (WGS) data from 4,495 ALS
cases and 1,925 controls. CAV1/CAV2 enhancers
deviate from the null distribution (diagonal),
revealing that the burden of variants measured in
CAV1/CAV2 enhancers is significantly associated
with risk of ALS even after correction for multiple
testing.
(C) Quantity of genetic material (bp) relative to CNS
enhancers derived from Hi-C data (Rhie et al.,
2018); CNS enhancers = 100. Upper two bars
denote total genetic material; lower two bars
denote ALS-associated genetic variants only. Gray
shading denotes material unique to CNS or tissue-
agnostic enhancers versus material shared by both
(white).
(D and E) CAV1-coding variants passing filtering
criteria are depicted in the table and figure. This
analysis utilized WGS data from 4,495 ALS cases
and 1,925 controls. One variant is present at higher
frequency in controls (orange arrow), and one
variant is present is multiple ALS patients (bold
arrow); all other variants were discovered in a single
ALS patient and zero controls.
As a secondary analysis, we obtained
summary statistics from 32,298 European
non-Finnish non-ALS controls (Karczew-
ski et al., 2020; Taliun et al., 2019). A larger
sample size facilitated re-analysis of tis-
sue-agnostic CAV1/CAV2 enhancers
within the same ALS cohort but using an
independent population matched control cohort. Re-applying
our pipeline revealed significant enrichment of ALS-associated
genetic variants within CAV1 and CAV2 enhancers compared
to the discovery cohort (n = 4,495, Data-Freeze-1; CAV1: p =
2.64 3 109, SKAT-O, 112 variants; CAV2: p = 7.30 3 108,
SKAT-O, 174 variants) and replication cohort (n = 1,685, Data-
Freeze-2; CAV1: p = 8.6 3 105, SKAT-O, 94 variants; CAV2:
p = 4.87 3 107, SKAT-O, 150 variants).
Genetic Variation within CAV1 Coding Sequence Is
Associated with ALS
It is likely that genetic variation within linked enhancer and cod-
ing regions can produce similar phenotypes. We tested for ALS-
associated genetic variation within CAV1 and CAV2 exons by
rare-variant burden testing using WGS data from 4,495 ALS
cases and 1,925 controls (Project MinE; Data-Freeze-1). In addi-
tion to filtering by MAF < 0.01 (van Rheenen et al., 2016), we




introduced a functional filter to identify variants that alter protein
function (STARMethods; Cingolani et al., 2012). InCAV1, but not
CAV2, coding sequence, we identified significant enrichment of
functional genetic variation in ALS patients (p = 0.03; 12 variants;
Firth logistic regression; beta = 1.47; Figures 1D and 1E). In total,
15 (0.3%) ALS patients carried a CAV1 coding variant compared
to 1 (0.05%) of controls (risk ratio = 6.4). Coding and enhancer
mutations occurred in independent individuals, which excludes
the possibility that the observed convergence is a consequence
of linkage disequilibrium.
Reduced CAV1 and CAV2 Expression in Patient-Derived
Cells Carrying an ALS-Associated Enhancer Variant
Burden testing derives power from aggregating mutations into a
single statistical test, but as a consequence, experimental eval-
Figure 2. Patient-Derived Lymphoblastoid Cell
Lines Carrying an ALS-Associated CAV-
Enhancer/Coding Variants Have Reduced
Expression of CAV1/CAV2 and Disrupted MLR
Lymphoblastoid cells were derived from neurologi-
cally normal controls (n = 3, black), ALS patients
without CAV-enhancer variants (n = 3, blue), ALS
patients carrying CAV1-coding mutations (n = 3,
magenta), and cells carrying a disease-associated
chr7:116222625T>C-CAV1/CAV2 enhancer variant
(red).
(A and B) Immunoblotting measurement of CAV1
protein expression relative to a-tubulin loading con-
trol with an example blot.
(C and D) qPCR measurement of CAV1 and CAV2
mRNA expression relative to mean expression in
normal controls; expression normalized relative to
loading control.
(E, G, and H) Measurement of MLR integrity by live-
cell imaging and GM1 labeling with CTxB. CTxB
fluorescence is plotted with example images. Scale
bar, 50 mm.
(F) CAV1 protein expression is plotted versus MLR
integrity as measured by CTxB fluorescence in the
same cell line, with regression line (dotted).
Data presented as mean ± 1 SD. *p < 0.05; **p < 0.01;
***p < 0.001.
uation is necessary to determine which indi-
vidual mutations are pathogenic: indeed, it
is likely that a significant proportion of
variants are not pathogenic (Lee et al.,
2012). Reduced CAV1 expression is toxic
to neurons (Head et al., 2010, 2011),
and therefore, we measured CAV1/CAV2
expression in lymphoblastoid cells derived
from ALS patients carrying CAV1/CAV2
enhancer variants: chr7:116222625T>C
and chr7:115994269:C>T (Table S3).
In cells carrying chr7:116222625T>C,
CAV1 protein (89% reduction; p = 0.05;
Mann-Whitney test; Figures 2A and 2B) and
mRNA (89% reduction; p = 0.003; Welch’s
t test; Figure 2C) and CAV2 mRNA (93%
reduction; p = 0.002; Welch’s t test; Figure 2D) expression was
significantly reduced compared to mean expression in cells
derived from neurologically normal controls. Unfortunately, immu-
noblotting for CAV2 was not possible due to lack of a sufficiently
specific antibody. Expressionwas also reduced compared to ALS
patients without an enhancer mutation (Figures 2A–2D).
Cells carrying chr7:115994269:C > T did not show reduced
expression of CAV1/CAV2 (data not shown). We speculate that
this mutationmay impact transcription only in CNS cells, or alter-
natively, this variant may be non-functional.
Impaired MLR Formation in Patient-Derived Cells
Carrying an ALS-Associated Enhancer Variant
Reduced CAV1/CAV2 function is proposed to be toxic
via disruption of MLR, leading to impaired cell signaling




(Sawada et al., 2019). We tested whether ALS-associated
enhancer variants that reduce CAV1/CAV2 expression also
impair MLR formation. MLR integrity was measured by expres-
sion of GM1 gangliosides as labeled by cholera-toxin B (CTxB)
(Aman et al., 2001; Day and Kenworthy, 2015; Sawada et al.,
2019). CTxB fluorescence is significantly reduced in lymphoblas-
toid cells carrying chr7:116222625T>C compared to cells
derived from neurologically normal controls (8% reduction; Fig-
ure 2E); fluorescence was also reduced compared to ALS pa-
tients without a CAV1/CAV2 enhancer variant (Figures 2E and
2G). Strikingly, in all cell lines, GM1 expression and CAV1 protein
expression are positively correlated (r = 0.89; p = 0.007; Pearson
correlation; Figure 2F), which is consistent with direct depen-
dence of MLR integrity on CAV1 function.
We hypothesized that CAV1-coding variants would produce a
similar effect on MLR formation. Consistent with this, CTxB
fluorescence is significantly reduced in lymphoblastoid cells car-
rying p.Met111Val-, p.Pro132Ala-, and p.Val155Ile-CAV1 muta-
tions compared to cells derived from neurologically normal con-
trols (p = 0.009; t test; Figure 2H).
CRISPR-SpCas9 Enhancer Editing Reduces CAV1/CAV2
Expression in Neurons
We have confirmed that patient-derived cells carrying an ALS-
associated CAV1/CAV2 enhancer mutation display reduced
CAV1/CAV2 expression and disrupted MLR, which is likely to
lead to neurotoxicity (Sawada et al., 2019). However, these ex-
periments were carried out in non-neuronal cells. To confirm
that disruption of the same enhancer is sufficient to reduce
CAV1/CAV2 expression in a human CNS-relevant neuronal
cell, we used CRISPR-SpCas9 editing to introduce indel muta-
Figure 3. CRISPR-Directed Perturbation of a
CAV-Enhancer Region Proximate to a Patient
Mutation Reduces CAV1/CAV2 Expression in
a Differentiated SH-SY5Y Neuronal Cell
(A) Sanger sequencing traces demonstrating
spCas9 cut site adjacent to PAM and subsequent
waveform decomposition in enhancer edited cells.
Position of chr7:116222625T>C mutation is indi-
cated. Black line indicates gRNA sequence.
(B) Indel distribution within CAV-enhancer region in
CRISPR-edited SH-SY5Y cells.
(C and D) qPCR measurement of CAV1 mRNA and
CAV2 mRNA reveals reduced expression in CAV-
enhancer and CAV1-exon CRISPR-edited neurons
compared to CRISPR editing of HPRT; expression
normalized relative to loading control.
Data presented as mean ± 1 SD. ****p < 0.0001.
tions proximal to the site of the
chr7:116222625T>C mutation in SH-
SY5Y cells, which were subsequently
differentiated into neurons.
Guide RNAs (gRNAs) were designed to
target a protospacer adjacent motif
(PAM) site 16 bp downstream of the
chr7:116222625T>C mutation site. Sanger
sequencing and waveform decomposition
analysis (Hsiau et al., 2018) revealed 72% editing efficiency in un-
differentiated SH-SY5Y cells (Figure 3A). The majority of intro-
duced changes were a single-nucleotide insertion
(chr7:116222638T>TT; Figure 3B). A commercially available
gRNA targetingCAV1 exon 2was chosen to introduce a nonsense
mutation and served as a positive control, and a commercially
available control gRNA targeting HPRT served as a negative con-
trol. CRISPR-SpCas9-editedSH-SY5Y cells were differentiated to
aneuronalphenotype; successful differentiationwasconfirmedby
altered expression of PAX6 (Figure S4A; Forster et al., 2016) and
increased total dendritic length (p = 0.01; paired t test; Figure S4B;
Forster et al., 2016). Differentiated cells were harvested, and RNA
was extracted for qPCR. We confirmed reduced expression of
CAV1 (>99% reduction; p < 0.0001; Welch’s t test) and CAV2
(>99% reduction; p < 0.0001) mRNA in enhancer edited cells (Fig-
ures 3C and 3D). CAV2 mRNA expression was reduced in the
context of enhancer editing but also by CAV1-coding editing,
which likely reflects interdependence between the two genes
(Drab et al., 2001). Extreme reductions in CAV1/CAV2 expression
are notable; however, phenotypic change in excess of editing effi-
ciency is well described and may be a consequence of CRISPR
interference (Gaj et al., 2017).
ALS-Associated CAV1/CAV2 Enhancer Mutation Is
Associated with TF Binding Sites
Pathogenic enhancer mutations may act via altered TF binding
(Karnuta and Scacheri, 2018). To identify potential changes in
TF binding associated with CAV1/CAV2 enhancer mutations,
we analyzed publicly available ChIP sequencing data (https://
genome.ucsc.edu; TF ChIP-seq Clusters from ENCODE 3,
version: 3 November 2018). We identified five DNA-binding




proteins associatedwith both the site of the chr7:116222625T>C
mutation and the cut site for our CRISPR-SpCas9-editing exper-
iment in at least one cell type: RAD21; CTCF; FOS; SMC3; and
CEBPB. However, introduced mutations did not significantly
alter the predicted strength of TF binding (STAR Methods;
Nguyen et al., 2018).
DISCUSSION
Genetic discoveries in ALS have focused on high effect variants
within coding genes in patients with autosomal dominant inher-
itance. The non-coding genome is thought to contain missing
heritability (Pallares, 2019). We developed an approach to
discover genetic association within gene enhancer elements.
Using our methodology, we successfully identified and validated
ALS-associated genetic variation within enhancer and coding re-
gions associated with CAV1; we therefore propose CAV1 to be
an ALS risk gene. It is notable that we did not identify ALS-asso-
ciated nonsense mutations within CAV1 or CAV2. CAV1/CAV2
nonsense mutations would dramatically reduce gene expression
irrespective of cell type or even developmental stage and may
manifest a broad range of phenotypes, including motor neuron
toxicity, but not specifically ALS. A traditional focus only on
loss-of-function coding variants may therefore have missed the
link between CAV1/CAV2 expression and ALS.
Our work builds upon previous observations that CAV1 function
is neuroprotective in neurodegenerative disease (Head et al.,
2010) and in ALS in particular (Sawada et al., 2019). Until now, it
was not clear whether CAV1 dysfunction was a cause or effect
of neuronal toxicity; our discovery of genetic risk associated
with CAV1/CAV2 expression places this pathway upstream in
the development of disease. Using patient-derived cells, we
have shown that ALS-associated genetic variation within CAV1/
CAV2 enhancers and CAV1 coding sequence reduces CAV1/
CAV2 expression and disrupts MLR, which is contingent with
impaired neurotrophic signaling and consequently neurodegener-
ation (Sawada et al., 2019). Moreover, CRISPR-SpCas9 perturba-
tion proximate to a CAV/CAV2 enhancer mutation reduced CAV1
and CAV2 expression in human neuronal cells, suggesting that
this enhancer region is functional within the CNS.
Enhancer function is thought to depend on the binding of TFs
(Koch et al., 2011). Current understanding of function within
enhancer regions is limited (Levo et al., 2015), in part because of
a paucity of variants with validated biological impact. This incom-
plete understanding is reflected in our failure to link a change in TF
binding to thechanges inCAV1/CAV2expressionweobserve.Our
discovery forms a platform for improved understanding of molec-
ular function within these regions. We propose that our approach,
namely the discovery of disease-associated genetic variation, is a
means of overcoming a reliance on unphysiological in vitro assays
to understand enhancer biology (Gasperini et al., 2020).
Our genetic study was performed in sporadic ALS cases. As a
result, we propose that the mutations we have identified are
likely to be risk factors rather than fully penetrant monogenic
causes of disease. Indeed, sporadic ALS is proposed to be a
multistep process involving both genetic and environmental in-
sults (Al-Chalabi et al., 2014). The association of CAV1 function
with neurotrophic signaling is consistent with this premise; iden-
tified deficient neurotrophic signaling in ALS has been proposed
as a risk factor that increases the vulnerability of motor neurons
to additional insults (Bemelmans et al., 2006; Ghavami et al.,
2014; Kowianski et al., 2018; Tooze and Schiavo, 2008).
The premise of personalized medicine for complex disease is
that gene-environment interactions leading to disease are likely
to be heterogeneous (Li et al., 2019). We suggest that, in a signif-
icant number of ALS patients, genetic mutations leading to
reduced CAV1/CAV2 function are a significant cause of neuronal
toxicity. Upregulation of CAV1 is in development as a therapeutic
tool (Head et al., 2011; US patent no. 8969077B2); our data sug-
gest that this could be applied to genetically selected ALS pa-
tients in a personalized medicine approach.
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Reagent or Resource Source Identifier
Antibodies
Anti-Caveolin-1 GeneTex #GTX100205; RRID:AB_1240559
Anti-Caveolin-1 Abcam #AB2910; RRID:AB_303405
a-tubulin Sigma #T9026; RRID:AB_477593
Anti-Pax6 Abcam #AB5790; RRID:AB_305110
Anti-mouse HRP-conjugate Promega #W4021; RRID:AB_430834
Anti-rabbit HRP-conjugate Promega #W4011; RRID:AB_430833
Donkey anti-rabbit Alexa568 secondary Invitrogen #A10042; RRID:AB_2534017
Donkey anti-mouse Alexa488 secondary Invitrogen #A-21202; RRID:AB_141607
Chemicals, Peptides and Recombinant Proteins
Alt-R S.p. Cas9 Nuclease V3 Integrated DNA technologies #1081059
Alt-R Cas9 Electroporation Enhancer Integrated DNA technologies #1075915
Dulbecco’s Modified Eagle medium Lonza #12-604F
RPMI-1640 medium with L-glutamine Lonza #BE12-702F
Neurobasal medium ThermoFisher Scientific #12348017
Penicillin-Streptomycin Sigma #P4333
Fibronectin Merck #FC010
10x Trypsin Sigma #59427C
Foetal bovine serum ThermoFisher Scientific #10270106
L-glutamine (200mM) ThermoFisher Scientific #25030081
Agarose Melford #MB1200
Ethidium bromide solution Sigma #E1510
VeriFi mix red PCRBio #PB10.42-01
Tri reagent Sigma #93289-100ML
M-MLV reverse transcriptase ThermoFisher Scientific #28025-013
5x First Strand buffer ThermoFisher Scientific #18057-018
0.1M Dithiothreitol ThermoFisher Scientific #707265ML
dNTP Mix ThermoFisher Scientific #10534823
SYBR Green Brilliant III master mix Agilent #600882
Random hexamer primer ThermoFisher Scientific #SO142
Pre-stained protein ladder Abcam #116028
Bradford reagent Bio-Rad #5000001




SigmaFAST Protease Inhibitor Cocktail tablets Sigma #S8820
PMSF protease inhibitor ThermoFisher Scientific #36978
Clarity Western ECL blotting substrate Bio-Rad #1705060S
TracrRNA Integrated DNA technologies #1072533
TE Buffer, RNase-free pH 8 ThermoFisher Scientific #AM9849
Dulbecco’s Phosphate Buffered Saline Sigma #D8537-500ML
Triton X-100 Sigma-Aldrich #T8787
Normal horse serum Vector #S-2000-20
Hoechst 33342 ThermoFisher Scientific #62249
(Continued on next page)






Further information and requests for resources and reagents should be directed to and will be fulfilled by the corresponding author,
Johnathan Cooper-Knock (j.cooper-knock@sheffield.ac.uk).
Materials Availability
All unique/stable reagents generated in this study are available from the Lead Contact without restriction.
Data and Code Availability
This study did not generate any unique datasets or code. Whole genome sequencing data is available through Project MinE (https://
www.projectmine.com/research/data-sharing/). A data access committee controls access to raw data, ensuring a FAIR data setup
(https://www.datafairport.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Selection of patients and controls for genetic sequencing
All 6,180 patients and 2,370 controls included in this study were recruited at specialized neuromuscular centers in the UK, Belgium,
Germany, Ireland, Italy, Spain, Turkey, the United States and the Netherlands (Project MinE ALS Sequencing Consortium, 2018).
Continued
Reagent or Resource Source Identifier
All-trans retinoic acid Sigma #R2625
BDNF PeproTech #450-02
N-2 supplement ThermoFisher Scientific #17502048




Pierce BCA Assay Protein Assay Kit ThermoFisher Scientific #23225
GenElute Mammalian Genomic DNA Miniprep Kit Sigma #G1N350
Direct-zol RNA Miniprep Kit Zymo Research #R2050
Neon Transfection System 10 mL Kit ThermoFisher Scientific #MPK1096
Alt-R CRISPR-Cas9 Control Kit, Human, 2 nmol Integrated DNA technologies #1072554
Experimental Models: Cell Lines
SH-SY5Y ATCC Cat.#CRL-2266
Patient and control LCL lines MNDA (UK) DNA Bank N/A
Oligonucleotides












PRISM 7 GraphPad N/A
ICE CRISPR analysis tool https://ice.synthego.com/#/ N/A
CRISPOR guide RNA design tool http://crispor.tefor.net/ N/A
CFX Maestro Bio-Rad N/A
Harmony High-Content Imaging and Analysis
Software
PerkinElmer N/A
FIJI (FIJI Is Just ImageJ) NIH N/A




Patients were diagnosedwith possible, probable or definite ALS according to the 1994 El-Escorial criteria (Brooks, 1994). All controls
were free of neuromuscular diseases and matched for age, sex and geographical location. Analysis focused on Data-Freeze-1
including 4,495 ALS patients and 1,925 controls; Data-Freeze-2 (released December 2019) was used for validation. After excluding
population outliers Data-Freeze-2 included 1,685 ALS patients and 445 controls.
Secondary analysis was performed using summary statistics derived from WGS of 32,298 European non-Finnish controls. This
cohort and the relevant analysis pipeline have been previously described (Karczewski et al., 2020).
The studywas approved by the South Sheffield Research Ethics Committee. Also, this study followed study protocols approved by
Medical Ethical Committees for each of the participating institutions. Written informed consent was obtained from all participating
individuals. All methods were performed in accordance with relevant national and international guidelines and regulations.
SH-SY5Y neuroblastoma cells
Human SH-SY5Y neuroblastoma cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Lonza) supplemented with
10% (v/v) fetal bovine serum (FBS) (Thermo-Fisher Scientific), 50 units/mL of penicillin and 50 mg/mL of streptomycin. Cell lines
were maintained at 5% CO2 in a 37C incubator and split every 3-4 days. All experimental work was performed using cells within
the range of 7-32 passages.
Patient-derived lymphoblastoid cells
Lymphoblastoid cell lines derived from Caucasian ALS patients (n = 9) and neurologically normal controls (n = 3), all of Northern Eu-
ropean descent, were obtained from the UK Motor Neurone Disease Association (MNDA) DNA Bank. Demographic details are pro-
vided in Table S6. Lymphoblastoid cells were cultured in RPMI 1640Medium (Lonza) supplemented with 2mM L-glutamine and 10%
(v/v) FBS. Cells were maintained at 5% CO2 in a 37
C incubator and split every 3-4 days.
METHOD DETAILS
High Throughput DNA sequencing and QC
Methods are described elsewhere (Project MinE ALS Sequencing Consortium, 2018). In brief, DNAwas extracted from venous blood
samples and quality was assessed by gel electrophoresis. DNA samples were sequenced using Illumina’s FastTrack services (San
Diego, CA, USA) on the Illumina HiSeq 2000 platform. Sequencing was 100 bp paired-end (~40 3 coverage) performed using PCR-
free library preparation. The Isaac pipeline (Raczy et al., 2013) was used for alignment to the hg19 reference genome as well as to call
single nucleotide variants (SNVs), insertions and deletions (indels), and larger structural variants (SVs). Variants not passing Isaac’s
quality filter were set to missing; non-autosomal chromosome and multi-allelic variants were excluded. Sample and SNP QC were
performed using PLINK (Chang et al., 2015; Purcell et al., 2007) and VCFtools (Danecek et al., 2011). Samples were excluded if miss-
ingness by sample < 10% across all 22 chromosomes. Remaining sample QC steps were performed on a set of high-quality biallelic
SNPs that had minor allele frequency (MAF) > 10%, missingness < 0.1%, were LD-pruned at an r2 threshold of 0.2, were not A/T or
C/GSNPs, did not lie in themajor histocompatibility complex (MHC) or LCT locus, and did not occur in the inversions on chromosome
8 or chromosome 17. The ~30,000 SNPs overlapping this set of SNPs and HapMap 3 (HM3) were used to calculate principal com-
ponents projecting the ALS cases and controls onto theHM3 samples. Samples of non-European ancestry, defined as further than 10
standard deviations from the European-ancestry populations in HM3, were excluded from further analysis. Samples with an
inbreeding coefficient > 3 s.d. from the mean of the distribution were excluded, as were unexpected related samples. Samples
with discordant sex information (comparing chromosome X genotypes and phenotype information) were excluded.
Variants with missingness > 5% were removed, as were variants out of Hardy-Weinberg equilibrium in controls (p < 13 106) and
monomorphic variants (induced by sample exclusions). Differential missingness between cases and controls was checked and var-
iants with p < 13 106were removed. Variants with extreme depth of coverage (> 6 s.d. from themean of the total depth distribution)
were also excluded. Finally, the mitochondrial, X and Y chromosomes were excluded from analysis. Approximately 10 million sites
were lost during variant QC.
Variant Filtering
ALS features a polygenic rare variant architecture (van Rheenen et al., 2016); therefore all searches for pathogenic variants in
enhancer and coding regions featured a filter for MAF within the Genome Aggregation Database (gnomAD) of < 1/100 control alleles
(Lek et al., 2016). Additional filtering varied between area reflecting differences in function. In enhancer regions variants were included
only if evolutionary conserved based on a LINSIGHT score > 0.8 (Huang et al., 2017). In coding regions we filtered for variants with
impact on protein function as defined by snpeff (Cingolani et al., 2012): Variants annotated HIGH/MODERATE/LOW impact were
included, but we excluded variants annotated ‘synonymous’ or ‘TF_binding_site_variant’ because these functions are independent
of amino acid sequence.
Cell lysis
Lymphoblastoid cells were lysed in urea lysis buffer [8M urea; 1% (w/v) DTT; 20% (w/v) SDS; 1.5M Tris pH 6.8; + dH2O) + PIC
(20mL/mL) + 1mMPMSF at room temperature (RT). Samples were sonicated at 50% amplitude for 10 s (SoniPrep 150, MSE) followed




by a 30 s incubation at RT (3x). Sampleswere then incubated at RT for 15minutes. Lysateswere centrifuged at 17,000xg for 5minutes
at RT. Total protein concentration within the supernatant was quantified using a Pierce BCA Protein Assay Kit (ThermoFisher Scien-
tific) according to the manufacturer’s instructions and absorbance was measured at 562nm on a PHERAstar FS spectrophotometer
(BMGBiotech). Lysatesweremixedwith 4x Laemmli buffer (277.8mMTris-HCl; 44.4% (v/v) glycerol; 4.4%SDS; 0.02%bromophenol
blue; 355mM2-mercaptoethanol; pH 6.8) and boiled at 95C for 5minutes. Protein extracts were fractionated on 12%SDSpolyacryl-
amide gels and electrophoretically transferred to nitrocellulose membranes.
Immunoblotting
Nitrocellulose membranes were initially blocked in 5% (w/v) milk (Marvel)/Tris Buffered Saline, with Tween 20 (TBST) (20mM Tris,
137mMNaCl, 0.2% (v/v) Tween 20, pH 7.6) for 1 hour at RT then probed using the relevant primary antibody overnight at 4C. Anti-
caveolin 1 (GeneTex) (1:500 dilution) and a-tubulin (Abcam) (1:2000 dilution) primary antibodies were detected using a horseradish
peroxidase (HRP)-conjugated rabbit secondary antibody and a HRP-conjugatedmouse secondary antibody, respectively (Promega)
(1:5000 dilution). Protein bands were visualized using ECL substrate (Bio-Rad) and the chemiluminescence signal was imaged using
a G:BOX (Syngene).
CRISPR editing of mammalian cell lines
Guide RNAs (gRNAs) were designed using the Crispor tool (http://crispor.tefor.net/) to target CAV-enhancer regions. Design was
guided by proximity to patient enhancer mutation sites, available protospacer adjacent motifs (PAM), and predicted on- and off-
target efficiencies. gRNAs targeting within 30bp either side of the patient enhancer mutation site (chr7:116222625, hg19) were
considered and screened for editing efficiency as below. One guide sequence (50 -UUGUAAUCAGGAAUUUUCCA-30) was most effi-
cient and chosen for subsequent experimentation. Validated, commercially available CRISPR control targeting HPRT (IDT) and CAV1
exon-targeting (ThermoFisher Scientific) gRNAs were also obtained (Table S5). gRNA duplexes were assembled from tracrRNA and
crRNA in a thermocycler according to manufacturer’s instructions under RNase-free conditions. Cells were cultured to ensure 70%–
90% confluency on the day of transfection. 1ml antibiotic-free DMEM (Lonza) was prepared and incubated in 24-well plates at 37C.
CRISPR/Cas9 Ribonucleoproteins were formed by complexing 240ng gRNA duplex with 1250ng Alt-R V3 Cas9 Protein (IDT) in 10 mL
buffer R (from 10 mL Neon transfection kit, ThermoFisher Scientific) - a 1:1 molar ratio - for 10 minutes. 100,000 viable cells were ali-
quoted per transfection and centrifuged at 400 x g for 4 minutes. Cells were washed in calcium- and magnesium-free Dulbecco’s
Phosphate Buffered Saline (Sigma) and centrifuged at 400 x g for 4 minutes. Cell pellets were resuspended in 10 mL buffer R con-
taining Cas9 protein and gRNA duplexes. 2 mL of 10.8 mM electroporation enhancer (IDT) was added and the solution mixed thor-
oughly to ensure a suspension of single cells. 10 mL of this mixture was loaded into a Neon transfection system (ThermoFisher
Scientific) and electroporated according to manufacturer’s instructions (1200V, 3 pulse, 20 s pulse width for SH-SY5Y cells). Cells
were then transferred to pre-warmed media in 24-well plates.
Determining CRISPR editing efficiency
Genomic DNAwas isolated from CRISPR-edited and control cells using a GenElute Mammalian DNAMiniprep Kit (Sigma) according
tomanufacturer’s instructions. A ~400bp region around the expected cas9 cut site was amplified by polymerase chain reaction using
VeriFi mix (PCRbio). Expected amplification was confirmed using gel electrophoresis, and the products were Sanger-sequenced.
Sequencing trace files were uploaded to ICE (https://ice.synthego.com) and an indel efficiency calculated.
Quantitative PCR (RT-PCR):
Cells were cultured until at least 70% confluent, lysed on ice using an appropriate volume of Tri Reagent (Sigma) for 5 minutes and
transferred to 1.5ml RNase-free tubes. Total RNA was extracted using a Direct-zol RNA Miniprep Kit (Zymo) according to manufac-
turer’s instructions, and RNA concentration confirmed using a NanoDrop spectrophotometer (ThermoFisher Scientific). 2 mg of total
RNA was then converted to cDNA by adding 1 mL 10mM dNTPs, 1 mL 40 mM random hexamer primer (ThermoFisher Scientific), and
DNase/RNase-free water to a total volume of 14 mL. This mixture was heated for 5 minutes at 70C then placed on ice for 5 minutes.
4 mL of 5x FS buffer, 2 mL 0.1M DTT, and 1 mL M-MLV reverse transcriptase (ThermoFisher Scientific) were then added and cDNA
conversion performed in a PCR thermocycler (37C for 50 minutes, 70C for 10 minutes). cDNA was amplified using RT-PCR with
Brilliant III SYBRGreen (Agilent) as permanufacturer’s instructions. Ct analysis was performed usingCFXMaestro software (BioRad).
Reference genes RPL13A and GAPDH were chosen for experiments involving lymphoblast cells and SH-SY5Y cells respectively, for
their relative stability between experiments in these cell lines (Hoerndli et al., 2004; Hruz et al., 2011). Relative mRNA expression
values were then calculated using the 2-DDCT method (Schmittgen and Livak, 2008). Low CAV2 expression leading to non-amplifica-
tion in one cell line was assigned a maximum CT value of 40 for one repeat (McCall et al., 2014).
SH-SY5Y neuronal differentiation
Human SH-SY5Y neuroblastoma cells were seeded at densities of either 5x104 cells per well of a 6-well culture plate, or 2x103 cells
per well of a 96-well culture plate in DMEM (Lonza) supplemented with 10% (v/v) FBS, 50 units/mL penicillin and 50 mg/mL of
streptomycin. 24 hours after seeding the media was changed to DMEM supplemented with 5% (v/v) FBS, 50 units/mL penicillin,
50 mg/mL of streptomycin, 4mM l-glutamine and 10 mM retinoic acid. After 72 hours, the medium was switched to neurobasal media




(ThermoFisher Scientific) containing 1% (v/v) N-2 supplement 100x, 50 units/mL penicillin, 50 mg/mL of streptomycin, 1% l-glutamine
and 50ng/mL human BDNF. Cells were cultured for an additional 3 days until fully differentiated.
To confirm neuronal differentiation blinded, semi-automated analysis of neurite length was performed using the SimpleNeurite-
Tracer plugin for FIJI (Longair et al., 2011). 2D images were converted to 8-bit grayscale and successive points along the midline
of a neural process were selected. The software automatically identified the path between the two points. Tracing accuracy was
improved using Hessian-based analysis of image curvatures. The AnalyzeSkeleton plugin (Arganda-Carreras et al., 2010) was
used to quantify the morphology of the traces.
Immunocytochemistry
SH-SY5Y cells were fixed with 4% paraformaldehyde for 15 minutes and washed 3x with PBS. Cells were blocked in 5% normal
horse serum containing 0.1% Triton X-100 for 1 hour at RT. All primary antibodies were diluted in blocking solution (anti-Caveo-
lin-1, 1:500; a-tubulin, 1:2000; anti-Pax6, 1:200). Cells were incubated in the primary antibody for 2 hours at RT and washed 3x in
PBS before incubation in the appropriate secondary antibody (1:1000 in PBS) for 1 hour at RT. Nuclear counterstain (Hoechst
33342) was applied for 10 minutes followed by a 3x wash in PBS. Cells were imaged using an Opera Phenix High Content Screening
System (PerkinElmer).
Live cell imaging
96-well culture plates were coated in plasma fibronectin (Merck) (5mg/mL in PBS) for 30 minutes prior to cell seeding. Excess fibro-
nectin was removed immediately before seeding lymphoblastoid cells at a density of 2x104 cells per well. Lymphoblastoid cells were
cultured in supplemented RPMImedia for 2 days prior to live-cell imaging.Media was removed and 5mg/mL labeling solution (Cholera
Toxin Subunit B [CTxB] + Hanks Balanced Salt Solution [HBSS]) was added to cell-containing wells and incubated for 45 minutes at
37C, 5%CO2. Nuclear counterstain (Hoechst 33342) was applied for the final 5 minutes of the incubation. The labeling solution was
removed, cells were washed 2x in PBS and incubated in 200mL pre-warmed HBSS for imaging. Live imaging was performed via
confocal microscopy using an Opera PhenixTM High-Content Screening System (PerkinElmer) at 37C, 5% CO2. Cells were visual-
ized at 40x magnification within a high-resolution z stack consisting of images at 0.5mm intervals through the entire nuclear volume of
the cell.
QUANTIFICATION AND STATISTICAL ANALYSIS
Immunoblotting and quantitative PCR
Statistical analysis was conducted in GraphPad Prism 7 (La Jolla, CA). All bar graphs show the mean ± SD. To identify statistical dif-
ferences between treatment groups utilized Welch’s unpaired t test.
Burden testing
The optimal unified test (SKAT-O) was used to perform burden testing in enhancer regions because it is optimized for large numbers
of samples and for regions where a significant number of variants may not be causal (Lee et al., 2012). SKAT tests upweight signif-
icance of rare variants according to a beta density function ofMAF inwhichwj=Beta(pj, a1, a2), where pj is the estimatedMAF for SNPj
using all cases and controls, and the parameters a1 and a2 are prespecified. Optimal values of a1 and a2 were chosen using TBK1
enhancers where it was hypothesized ALS-associated should be present. Increasing values of a2 correspond to a relative upweight-
ing of increasingly rare variants; optimumALS-association was discovered for a2 = 250 (a2 = 25, p = 0.2; a2 = 250, p = 0.003; a2 = 2500,
p = 0.01); therefore a2 = 250 was chosen for all further statistical tests.
When variants are expected to have equivalent functional impact SKAT can lose power (Basu and Pan, 2011) and therefore in cod-
ing regions where variant filtering was more stringent and based on functional as well as population/evolution observations Firth lo-
gistic regression was preferred. To adjust for confounders including population structure, burden testing used the first ten eigenvec-
tors generated by principal components analysis of common variant profiles, and sex as covariates.
For the secondary analysis utilizing 32,298 European non-Finnish controls rare-variant burden testing was applied as before,
except that sex and eigenvectors were not available for use as covariates.
Modeling of TF binding
Candidate TF were identified from ChIP-sequencing data clusters via the UCSC genome browser (https://genome.ucsc.edu track:
‘Transcription Factor ChIP-seq Clusters from ENCODE 3, version: 3 Nov 2018’). Clusters associated with chr7:116222625T > Cwere
first identified, and then cross-referenced with other ALS-associated CAV enhancer variants (Table S3) and common TF identified.
Changes in putative TF-binding capacity between wild-type, mutant and CRISPR/SpCas9-edited sequences associated with the
chr7:116222625T > C mutation were then identified using position specific scoring matrices (http://rsat.sb-roscoff.fr/
matrix-scan-quick_form.cgi ENCODE human TFs 2018 03: ‘CEBPB_disc1’, ‘RAD21_disc1’, ‘CTCF_disc1’). Relative weights for
each TF/sequence combination were compared.
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Gene Target Chromosome Start Finish Tissue
CAV1 chr7 116474804 116476617 Tissue-agnostic
CAV1 chr7 116057349 116058637 Tissue-agnostic
CAV1:CAV2 chr7 116202174 116202561 Tissue-agnostic
CAV1:CAV2 chr7 115898310 115902716 Tissue-agnostic
CAV1:CAV2 chr7 116215990 116219157 Tissue-agnostic
CAV1:CAV2 chr7 115992110 115999387 Tissue-agnostic
CAV1:CAV2 chr7 116185994 116188883 Tissue-agnostic
CAV1:CAV2 chr7 116209195 116214933 Tissue-agnostic
CAV1:CAV2 chr7 116196622 116201351 Tissue-agnostic
CAV1:CAV2 chr7 116149154 116154310 Tissue-agnostic
CAV1:CAV2 chr7 116220723 116224531 Tissue-agnostic
CAV1:CAV2 chr7 116033656 116036708 Tissue-agnostic
CAV2 chr7 116078147 116088487 Tissue-agnostic
CAV2 chr7 115954125 115959325 Tissue-agnostic
CAV2 chr7 116180927 116184847 Tissue-agnostic
CAV2 chr7 116231455 116233866 Tissue-agnostic
CAV2 chr7 116065132 116068292 Tissue-agnostic
CAV2 chr7 116094877 116096147 Tissue-agnostic
CAV2 chr7 116003024 116004444 Tissue-agnostic
CAV2 chr7 116071887 116076515 Tissue-agnostic
CAV2 chr7 116176051 116176914 Tissue-agnostic
CAV2 chr7 116261779 116262057 Tissue-agnostic
CAV2 chr7 116062851 116064462 Tissue-agnostic
CAV2 chr7 116134797 116136789 Tissue-agnostic
CAV2 chr7 116154567 116155823 Tissue-agnostic
CAV2 chr7 116104521 116107038 Tissue-agnostic
CAV1 chr7 115816693 115817206 CNS
CAV1 chr7 115853719 115854235 CNS
CAV1 chr7 115870180 115870885 CNS
CAV1 chr7 115871349 115873794 CNS
CAV1 chr7 115910552 115913260 CNS
CAV1 chr7 115913518 115914249 CNS
CAV1 chr7 115955578 115958367 CNS
CAV1 chr7 115967434 115969066 CNS
CAV1 chr7 115993415 115996411 CNS
CAV1 chr7 116034665 116036373 CNS
CAV1 chr7 116066587 116067242 CNS
CAV1 chr7 116073579 116076380 CNS
CAV1 chr7 116080916 116084930 CNS
CAV1 chr7 116094659 116096095 CNS
CAV1 chr7 116103858 116107331 CNS
CAV1 chr7 116118084 116119473 CNS
CAV1 chr7 116149961 116153401 CNS
CAV1 chr7 115898864 115900695 CNS
Table S1: Enhancer regions associated with CAV1/CAV2 or 
TBK1 expression in different tissues. Related to Figure 1
CAV1 chr7 115867068 115868903 CNS
CAV1 chr7 115996955 115998734 CNS
CAV1 chr7 116170083 116171009 CNS
CAV1 chr7 116175367 116176059 CNS
CAV1 chr7 116181441 116182810 CNS
CAV1 chr7 116182954 116183855 CNS
CAV1 chr7 116186806 116188332 CNS
CAV1 chr7 116195961 116196301 CNS
CAV1 chr7 116199565 116200132 CNS
CAV1 chr7 116206178 116207412 CNS
CAV1 chr7 116213507 116219235 CNS
CAV1 chr7 116221274 116225513 CNS
CAV1 chr7 116207998 116213360 CNS
CAV1 chr7 116227556 116229293 CNS
CAV1 chr7 116268838 116269440 CNS
CAV1 chr7 116273324 116274010 CNS
CAV1 chr7 116327276 116331188 CNS
CAV1 chr7 116331287 116334384 CNS
CAV1 chr7 116345275 116345781 CNS
CAV1 chr7 116345958 116349052 CNS
CAV1 chr7 116353124 116354955 CNS
CAV1 chr7 116355221 116357861 CNS
CAV1 chr7 116411044 116413659 CNS
CAV1 chr7 116415730 116419494 CNS
CAV1 chr7 116421735 116423410 CNS
CAV1 chr7 116341997 116343027 CNS
CAV1 chr7 116439854 116443746 CNS
CAV1 chr7 114429291 114431269 CNS
CAV1 chr7 114525449 114526553 CNS
CAV1 chr7 114529275 114530372 CNS
CAV1 chr7 114567780 114569045 CNS
CAV1 chr7 114569345 114571951 CNS
CAV1 chr7 114573849 114576684 CNS
CAV1 chr7 114583410 114585966 CNS
CAV1 chr7 114627975 114630075 CNS
CAV1 chr7 114648866 114650794 CNS
CAV1 chr7 114680511 114680894 CNS
CAV1 chr7 114870292 114872289 CNS
CAV1 chr7 114939946 114941012 CNS
CAV1 chr7 114992058 114993494 CNS
CAV1 chr7 115186013 115186673 CNS
CAV1 chr7 115301123 115304100 CNS
CAV1 chr7 115304366 115304820 CNS
CAV1 chr7 115310813 115313335 CNS
CAV1 chr7 115317812 115318384 CNS
CAV1 chr7 115318462 115319029 CNS
CAV1 chr7 115737105 115737568 CNS
CAV1 chr7 116502110 116504190 CNS
CAV1 chr7 116511658 116512938 CNS
CAV1 chr7 116551519 116552444 CNS
CAV1 chr7 116638294 116639676 CNS
CAV1 chr7 116645209 116646095 CNS
CAV1 chr7 116701473 116702466 CNS
CAV1 chr7 116738137 116738529 CNS
CAV1 chr7 116738883 116739229 CNS
CAV1 chr7 116764255 116764795 CNS
CAV1 chr7 116764919 116766070 CNS
CAV1 chr7 116771574 116774341 CNS
CAV1 chr7 116797868 116798377 CNS
CAV1 chr7 116869939 116871410 CNS
CAV1 chr7 116908705 116911053 CNS
CAV1 chr7 116923096 116924277 CNS
CAV1 chr7 117222645 117223108 CNS
CAV1 chr7 117305812 117306347 CNS
CAV1 chr7 117468242 117468792 CNS
CAV1 chr7 114458233 114460475 CNS
CAV1 chr7 114572709 114573331 CNS
CAV1 chr7 114785263 114786500 CNS
CAV1 chr7 115670883 115671400 CNS
CAV1 chr7 116899318 116900524 CNS
TBK1 chr12 64976982 64978649 Tissue-agnostic
TBK1 chr12 64849299 64852075 Tissue-agnostic
TBK1 chr12 64855048 64856317 Tissue-agnostic
TBK1 chr12 65194398 65194833 Tissue-agnostic
TBK1 chr12 65139887 65142519 Tissue-agnostic
TBK1 chr12 64349522 64350375 Tissue-agnostic
TBK1 chr12 64988381 64990575 Tissue-agnostic
TBK1 chr12 64852385 64854077 Tissue-agnostic
TBK1 chr12 65058182 65079989 Tissue-agnostic
TBK1 chr12 64479266 64484481 Tissue-agnostic
TBK1 chr12 64943421 64943781 Tissue-agnostic
TBK1 chr12 64953898 64955793 Tissue-agnostic
TBK1 chr12 64490881 64493995 Tissue-agnostic
Figure S1: qPCR measurement of TBK1 mRNA expression relative to mean expression in normal 
controls. Expression normalised relative to loading control. Related to Figure 1. 
Variants ALS Frequency
Control 
Frequency Cohort Variants ALS Frequency
Control 
Frequency Cohort
chr7:115899988:T:C 0.00022 0 D(i) chr7:115994719:G:A 0.000889878 0.001038961 D (ii)
chr7:115900605:A:G 0.00022 0 D(i) chr7:115994770:C:G 0.000222469 0 D (ii)
chr7:115994269:C:T 0.00044 0 D(i) chr7:115994869:C:T 0.000222469 0 D (ii)
chr7:115994303:G:A 0.00044 0 D(i) chr7:115994875:C:T 0.000222469 0 D (ii)
chr7:115994310:A:G 0 0.00052 D(i) chr7:115995110:A:G 0.000444939 0 D (ii)
chr7:115994595:T:G 0.00022 0 D(i) chr7:115995386:G:A 0 0.000519481 D (ii)
chr7:115994627:T:C 0.00022 0 D(i) chr7:115995411:C:G 0.000222469 0 D (ii)
chr7:115994719:G:A 0.00089 0.00104 D(i) chr7:115996247:A:G 0.000222469 0 D (ii)
chr7:115994770:C:G 0.00022 0 D(i) chr7:115996338:G:C 0.000222469 0 D (ii)
chr7:115994869:C:T 0.00022 0 D(i) chr7:116035733:C:A 0.000444939 0 D (ii)
chr7:115994875:C:T 0.00022 0 D(i) chr7:116152216:C:T 0.000222469 0.001038961 D (ii)
chr7:115995110:A:G 0.00044 0 D(i) chr7:116175470:A:G 0.001557286 0.003116883 D (ii)
chr7:115995386:G:A 0 0.00052 D(i) chr7:116175631:T:A 0 0.000519481 D (ii)
chr7:115995411:C:G 0.00022 0 D(i) chr7:116175647:T:G 0.000222469 0 D (ii)
chr7:115996247:A:G 0.00022 0 D(i) chr7:116181928:T:C 0 0.000519481 D (ii)
chr7:115996338:G:C 0.00022 0 D(i) chr7:116182530:A:G 0.000222469 0 D (ii)
chr7:115996639:T:G 0.00022 0 D(i) chr7:116182646:A:G 0.000667408 0.003116883 D (ii)
chr7:116034151:T:C 0.00022 0 D(i) chr7:116182790:T:C 0 0.000519481 D (ii)
chr7:116035733:C:A 0.00044 0 D(i) chr7:116211360:G:A 0.000444939 0.004675325 D (ii)
chr7:116152216:C:T 0.00022 0.00104 D(i) chr7:116211574:C:T 0.000667408 0.000519481 D (ii)
chr7:116198357:C:T 0.00089 0 D(i) chr7:116212628:A:G 0.000222469 0 D (ii)
chr7:116199522:T:C 0.00022 0 D(i) chr7:116212861:A:G 0.000222469 0 D (ii)
chr7:116200589:T:A 0.00022 0 D(i) chr7:116213876:A:T 0.000222469 0.001038961 D (ii)
chr7:116200705:C:T 0.00022 0 D(i) chr7:116217283:C:G 0.000222469 0 D (ii)
chr7:116200719:C:A 0.00022 0 D(i) chr7:116222625:T:C 0.000444939 0 D (ii)
chr7:116200953:A:T 0.00022 0 D(i) chr7:116223328:A:G 0.000667408 0.000519481 D (ii)
chr7:116200959:G:T 0 0.00052 D(i) chr7:116223448:C:T 0.000222469 0 D (ii)
chr7:116201160:T:C 0 0.00052 D(i) chr7:116224152:G:A 0.002002225 0.007272727 D (ii)
chr7:116201160:T:G 0 0.00052 D(i) chr7:116273953:C:T 0 0.000519481 D (ii)
chr7:116211360:G:A 0.00044 0.00468 D(i) chr7:116273989:A:G 0.000222469 0.000519481 D (ii)
chr7:116211574:C:T 0.00067 0.00052 D(i) chr7:116327730:T:C 0.000444939 0.000519481 D (ii)
chr7:116212628:A:G 0.00022 0 D(i) chr7:116330812:T:C 0.000222469 0 D (ii)
chr7:116212861:A:G 0.00022 0 D(i) chr7:116331129:T:C 0 0.000519481 D (ii)
chr7:116213876:A:T 0.00022 0.00104 D(i) chr7:116333491:C:T 0.000222469 0 D (ii)
chr7:116217283:C:G 0.00022 0 D(i) chr7:116333773:C:A 0 0.000519481 D (ii)
chr7:116222625:T:C 0.00044 0 D(i) chr7:116342514:T:C 0.000222469 0 D (ii)
chr7:116223328:A:G 0.00067 0.00052 D(i) chr7:116345315:A:G 0.000222469 0 D (ii)
chr7:116223448:C:T 0.00022 0 D(i) chr7:116346600:T:C 0.000222469 0.000519481 D (ii)
chr7:116224152:G:A 0.00200 0.00727 D(i) chr7:116347870:C:G 0.000222469 0 D (ii)
chr7:116474819:G:T 0.00067 0 D(i) chr7:116355771:G:A 0.000222469 0 D (ii)
chr7:115957412:G:A 0.00022 0 D(i) chr7:116356905:C:A 0.002892102 0.001038961 D (ii)
chr7:115957415:T:C 0.00022 0 D(i) chr7:116356905:C:T 0.000222469 0.000519481 D (ii)
chr7:115957440:G:A 0.00022 0 D(i) chr7:116357813:A:G 0.000444939 0 D (ii)
Table S2: Genetic variants wihin CAV1/CAV2 enhancer regions. D(i)=Discovery cohort; 
tissue-agnostic enhancers; D(ii)=Discovery cohort, CNS enhancers; R=Replicartion cohort. 
Related to Figure 1.
chr7:115957498:C:A 0.00022 0 D(i) chr7:116412712:C:T 0.000222469 0 D (ii)
chr7:115957577:G:A 0.00022 0.00052 D(i) chr7:116415873:G:T 0.000222469 0 D (ii)
chr7:116004321:G:A 0.00044 0 D(i) chr7:116415881:T:G 0.000222469 0 D (ii)
chr7:116063605:A:G 0 0.00052 D(i) chr7:116415938:C:G 0.000222469 0 D (ii)
chr7:116063624:T:C 0.00022 0 D(i) chr7:116416799:C:T 0.001112347 0 D (ii)
chr7:116064199:T:C 0.00022 0 D(i) chr7:116416941:A:G 0.000222469 0 D (ii)
chr7:116087637:G:A 0.00022 0 D(i) chr7:116417019:A:G 0.000222469 0 D (ii)
chr7:116181928:T:C 0 0.00052 D(i) chr7:116419236:G:T 0.001112347 0.001038961 D (ii)
chr7:116182530:A:G 0.00022 0 D(i) chr7:116422352:C:T 0.000222469 0 D (ii)
chr7:116182646:A:G 0.00067 0.00312 D(i) chr7:116422362:G:T 0.000222469 0 D (ii)
chr7:116182790:T:C 0 0.00052 D(i) chr7:116422617:T:C 0.000889878 0.001558442 D (ii)
chr7:116184017:A:T 0.00912 0.00987 D(i) chr7:116422623:C:A 0.005116796 0.002597403 D (ii)
chr7:116184130:T:A 0.00044 0 D(i) chr7:116441514:T:C 0.000222469 0 D (ii)
chr7:116232009:G:C 0 0.00052 D(i) chr7:116441539:C:T 0 0.000519481 D (ii)
chr7:116233640:T:C 0 0.00052 D(i) chr7:116441559:C:A 0 0.000519481 D (ii)
chr7:114430787:C:G 0.008008899 0.008311688 D (ii) chr7:116441604:C:A 0.003114572 0.001038961 D (ii)
chr7:114530323:G:A 0.000222469 0.000519481 D (ii) chr7:116442636:T:A 0.000222469 0 D (ii)
chr7:114570572:C:A 0 0.000519481 D (ii) chr7:116442680:C:T 0.000222469 0 D (ii)
chr7:114571016:G:A 0 0.000519481 D (ii) chr7:116443482:C:T 0.000222469 0 D (ii)
chr7:114571375:G:C 0.000222469 0 D (ii) chr7:116502532:G:C 0 0.001038961 D (ii)
chr7:114571427:G:T 0 0.000519481 D (ii) chr7:116502617:C:G 0.000222469 0 D (ii)
chr7:114574678:G:A 0.000222469 0 D (ii) chr7:116502985:G:C 0.000222469 0 D (ii)
chr7:114575111:A:C 0.001334816 0 D (ii) chr7:116774049:T:C 0.000222469 0 D (ii)
chr7:114575748:A:G 0.000444939 0 D (ii) chr7:116774169:C:T 0.000222469 0 D (ii)
chr7:114583529:T:C 0.000222469 0 D (ii) chr7:116774262:G:T 0.004004449 0.000519481 D (ii)
chr7:114649995:C:A 0.000222469 0 D (ii) chr7:116797872:G:A 0.000222469 0 D (ii)
chr7:114870400:T:G 0.000222469 0 D (ii) chr7:116909821:G:A 0.000222469 0 D (ii)
chr7:114870987:C:T 0.000222469 0 D (ii) chr7:116910136:C:A 0 0.000519481 D (ii)
chr7:114871000:G:C 0.000222469 0 D (ii) chr7:116910162:C:G 0.000222469 0 D (ii)
chr7:114871004:A:T 0 0.000519481 D (ii) chr7:116910505:A:C 0.000222469 0 D (ii)
chr7:114871090:C:T 0.000889878 0.001038961 D (ii) chr7:117306108:T:C 0.000222469 0 D (ii)
chr7:114871798:T:C 0.000667408 0 D (ii) chr7:117468457:C:T 0.000889878 0.001038961 D (ii)
chr7:114940467:A:G 0.000444939 0 D (ii) chr7:117468773:A:G 0.000444939 0.000519481 D (ii)
chr7:114940537:T:C 0 0.000519481 D (ii) chr7:114430749:G:T 0.000593472 0 R
chr7:114940606:C:T 0.000222469 0 D (ii) chr7:114870400:T:G 0.001186944 0 R
chr7:115302267:G:A 0.000222469 0 D (ii) chr7:114871090:C:T 0.000593472 0 R
chr7:115302388:C:T 0.000222469 0 D (ii) chr7:114871798:T:C 0.000593472 0 R
chr7:115302422:A:G 0.000222469 0 D (ii) chr7:114940077:A:G 0.000593472 0 R
chr7:115302425:G:T 0.000222469 0 D (ii) chr7:114940422:T:A 0.000593472 0 R
chr7:115312834:C:T 0.000222469 0 D (ii) chr7:115302422:A:G 0.000593472 0 R
chr7:115318030:G:A 0.000222469 0 D (ii) chr7:115303637:A:G 0.000593472 0 R
chr7:115318066:G:A 0.001334816 0.000519481 D (ii) chr7:115313234:T:G 0.000593472 0 R
chr7:115318198:G:A 0.000222469 0 D (ii) chr7:115318066:G:A 0.002967359 0.002247191 R
chr7:115318232:C:T 0.000444939 0.000519481 D (ii) chr7:115318495:C:T 0.000593472 0 R
chr7:115318257:A:T 0.000222469 0 D (ii) chr7:115912442:G:A 0.000593472 0 R
chr7:115318267:C:G 0.000222469 0 D (ii) chr7:115968420:C:T 0.001186944 0 R
chr7:115318323:G:C 0.000222469 0 D (ii) chr7:115968431:A:G 0.000593472 0 R
chr7:115318339:G:A 0.000222469 0 D (ii) chr7:115994330:C:T 0.000593472 0 R
chr7:115670928:A:G 0.001334816 0.001038961 D (ii) chr7:115995441:A:C 0.000593472 0 R
chr7:115867898:G:A 0.000222469 0 D (ii) chr7:116152067:C:T 0.000593472 0 R
chr7:115899988:T:C 0.000222469 0 D (ii) chr7:116175470:A:G 0.000593472 0 R
chr7:115900605:A:G 0.000222469 0 D (ii) chr7:116175798:A:G 0.000593472 0 R
chr7:115911421:A:G 0.000222469 0 D (ii) chr7:116223751:C:G 0.001186944 0 R
chr7:115911791:T:G 0 0.000519481 D (ii) chr7:116273806:G:A 0.000593472 0 R
chr7:115957412:G:A 0.000222469 0 D (ii) chr7:116327730:T:C 0.000593472 0 R
chr7:115957415:T:C 0.000222469 0 D (ii) chr7:116331111:T:C 0.000593472 0 R
chr7:115957440:G:A 0.000222469 0 D (ii) chr7:116342272:T:C 0.000593472 0 R
chr7:115957498:C:A 0.000222469 0 D (ii) chr7:116347329:T:C 0.000593472 0 R
chr7:115957577:G:A 0.000222469 0.000519481 D (ii) chr7:116416799:C:T 0.000593472 0 R
chr7:115968420:C:T 0.000222469 0.000519481 D (ii) chr7:116419236:G:T 0.001186944 0 R
chr7:115968429:G:A 0 0.000519481 D (ii) chr7:116422617:T:C 0.000593472 0 R
chr7:115968452:C:T 0.000222469 0 D (ii) chr7:116422623:C:A 0.007121662 0 R
chr7:115994269:C:T 0.000444939 0 D (ii) chr7:116645747:A:C 0.000593472 0 R
chr7:115994303:G:A 0.000444939 0 D (ii) chr7:116774262:G:T 0.005341246 0.004494382 R
chr7:115994310:A:G 0 0.000519481 D (ii) chr7:116910136:C:A 0.000593472 0 R
chr7:115994595:T:G 0.000222469 0 D (ii) chr7:117468457:C:T 0.000593472 0 R
chr7:115994627:T:C 0.000222469 0 D (ii)
Figure S2: Increased dendrite length and altered PAX6 expression confirms successful neuronal differentiation 
of SH-SY5Y cells. Neuronal differentiated SH-SY5Y cells have increased dendrite length (A, *p<0.05, 
paired t-test, Forster et al., 2016). PAX6 is a transcription factor with an important role in neuronal 
development; reduced expression of PAX6 is concurrent with neuronal differentiation of Sh-SY5Y cells 
(B, Forster et al., 2016). Related to Figure 3.
A B
DNA oligos
qPCR RPL13A FWD 5'-CAAGCGGATGAACACCAACC-3'
qPCR RPL13A REV 5'-TTTTGTGGGGCAGCATACCT-3'
qPCR GAPDH FWD 5'-CAACTTTGGTATCGTGGAAGGAC-3'
qPCR GAPDH REV 5'-ACAGTCTTCTGGATGGCAGTG-3'
qPCR Pax6 FWD 5'-GTGCCCGTCCATCTTTGCTT-3'
qPCR Pax6 REV 5'-GCGCCCATCTGTTGGTTTTC-3'
qPCR CAV1 FWD 5’-CCAAGGAGATCGACCTGGTCAA– 3’ 
qPCR CAV1 REV 5’-GCCGTCAAAACTGTGTGTCCCT– 3’ 
qPCR CAV2 5'-TTCTCTTTGCCACCCTCAGCTG-3'
qPCR CAV2 5'-GAAGCATCGTCCTACGCTCGTA-3'
sequencing primers CAV enhancer 1 FWD 5'-ACCCTCCAGCACTAATGGACTT-3'
sequencing primers CAV enhancer 1 REV 5'-CCTGAGTTGATGACCCTTCTCCT-3'
sequencing primers CAV enhancer 2 FWD 5'-CTGCATACGCTATACCCGGC-3'
sequencing primers CAV enhancer 2 REV 5'-AGGTGTTTCGCTCCTCTGTC-3'
sequencing primers CAV exon FWD 5'-AGTACAGAGGGGTGTGGTGT-3'
sequencing primers CAV exon REV 5'-GGCTTACCTTGACCACGTCA-3'
RNA Oligos (crRNA)
crRNA targeting CAV enhancer 5'-UUGUAAUCAGGAAUUUUCCA+modified linker-3'
crRNA targeting CAV exon 5'-AGUGUACGACGCGCACACCA+modified linker-3'
Table S3: DNA and RNA oligonucleotide sequences. Related to STAR Methods, 'CRISPR 



























Table S4: Demographic information for patient-derived lymphoblastoid 
cell lines. Related to STAR Methods, 'Patient-derived lymphoblastoid cells'
